Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer

about

Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer

Item

http://www.wikidata.org/entity/Q28074156

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@ast

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@en

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@nl

type

Item

label

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@ast

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@en

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@nl

prefLabel

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@ast

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@en

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@nl

P1476

Palbociclib: A New Option for ...... e, HER2-Negative Breast Cancer

@en

P2093

Bowles HJ

http://www.w3.org/2001/XMLSchema#string

Clarke KL

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Combination anastrozole and fulvestrant in metastatic breast cancer

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Molecular portraits of human breast tumours

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Signaling through cyclin D-dependent kinases.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.

P304

577-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JADPRO.2015.6.6.6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27648347

http://www.w3.org/2001/XMLSchema#string

P932

5017548

http://www.w3.org/2001/XMLSchema#string